Skip to main content

Deerfield Management Company, L.P.'s Form 4 filing

Acutus Medical, Inc. (AFIB) · filed Jul 21, 2021

Accession no.
0001193805-21-001059
Filed
Jul 21, 2021, 5:14 PM ET
Trade date
Jul 19, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market purchases total $15.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Deerfield Management Company, L.P.CIK 0001009258Director, 10% Owner, Other: Director by Deputization
Deerfield Mgmt L.P.CIK 0001010823Director, 10% Owner, Other: Director by Deputization
Deerfield Partners, L.P.CIK 0001301041Director, 10% Owner, Other: Director by Deputization
Flynn James ECIK 0001352546Director, 10% Owner, Other: Director by Deputization
Deerfield Private Design Fund III, L.P.CIK 0001603333Director, 10% Owner, Other: Director by Deputization
Deerfield Mgmt III, L.P.CIK 0001610540Director, 10% Owner, Other: Director by Deputization

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 19, 2021Common StockPPurchaseAcquired+390,836$14.00+$5,471,7041,974,638Indirect
Jul 19, 2021Common StockPPurchaseAcquired+680,592$14.00+$9,528,2883,438,589Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.

Read the full filing on SEC EDGAR (opens in a new tab)